Inflammatory Myopathies Treatment Guidelines

Introduction to IVIG Therapy

The Mayo Clinic guidelines recommend IVIG for specific types of idiopathic inflammatory myopathies (IIM) in certain circumstances, such as dermatomyositis with dysphagia, notable weight loss, severe rash, or severe weakness 1
IVIG has shown efficacy in dermatomyositis based on a placebo-controlled trial where 12 of 15 patients had improvement in muscle strength, rash, and activities of daily living 1

A definitive diagnosis of the specific type of myositis is necessary before considering IVIG therapy, including muscle biopsy, comprehensive autoantibody testing, and EMG/NCS confirmation 1
Serum IgA levels should be checked before IVIG administration, as IgA deficiency may lead to fever, infusion reactions, or severe anaphylaxis 1

The American College of Rheumatology recommends biologic DMARDs, such as Humira, for worsening arthralgias in patients with rheumatoid arthritis 1
Mycophenolate mofetil (MMF) has shown efficacy in inflammatory myopathies and may be considered at a dosage of 500 mg twice daily, gradually increased to 2 g/day 1
Rituximab has shown promise in refractory inflammatory myopathies, with significant reduction in muscle enzyme levels and improvements in strength 1

IVIG therapy should be reserved for specific inflammatory myopathies with severe manifestations that have failed conventional therapy, including corticosteroids and conventional immunosuppressants 1
A more appropriate approach for patients with unspecified myositis would be to establish a definitive diagnosis, proceed with planned biologic DMARDs for RA symptoms, and consider alternative therapies such as mycophenolate mofetil or rituximab if inflammatory myopathy is confirmed 1